Evidence map›Paper›PMID 33481931›Full record

Trial reportPloS one2021

Provision of HIV viral load testing services in Zimbabwe: Secondary data analyses using data from health facilities using the electronic Patient Monitoring System.

Tsitsi Apollo, Kudakwashe C Takarinda, Andrew Phillips, Chiratidzo Ndhlovu, Frances M Cowan

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Observational
  5. Article
  6. Article
  7. Article
  8. HIV Viral Re-Suppression on Second-Line ART in Southern Zimbabwe.International journal of environmental research and public health · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Tsitsi ApolloDepartment of HIV and TB, Ministry of Health and Child Care, Harare, Zimbabwe.ORCID 0000-0001-9881-0914
Kudakwashe C TakarindaDepartment of HIV and TB, Ministry of Health and Child Care, Harare, Zimbabwe.
Andrew PhillipsInstitute for Global Health, UCL, London, United Kingdom.
Chiratidzo NdhlovuDepartment of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Frances M CowanCentre for Sexual Health and HIV/AIDS Research (CeSHHAR), Harare, Zimbabwe.
University of Zimbabwe · ZWLiverpool School of Tropical Medicine · GBMinistry of Health and Child Welfare · ZWUniversity College London · GB

Funding

Training for Research Excellence and MeNtorship in Tuberculosis (TRENT)D43TW009539 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI METCALFE, JOHN ZAPATA · 2013 to 2022
$2.9M
FIC NIH HHS D43 TW009539
6 · The paper itself

Abstract

introductionRoutine viral load (VL) testing among persons living with Human Immunodeficiency Virus (PLHIV) enables earlier detection of sub-optimal antiretroviral therapy (ART) adherence and for appropriate management of treatment failure. Since adoption of this policy by Zimbabwe in 2016, the extent of implementation is unclear. Therefore we set out to determine among PLHIV ever enrolled on ART from 2004-2017 and in ART care for ≥12 months at health facilities providing ART in Zimbabwe: numbers (proportions) with VL testing uptake, VL suppression and subsequently switched to 2nd-line ART following confirmed virologic failure. MATERIALS AND

methodsWe used retrospective data from the electronic Patient Monitoring System (ePMS) in which PLHIV on ART are registered at 525 public and 4 private health facilities.

resultsAmong the 392,832 PLHIV in ART care for ≥12 months, 99,721 (25.4%) had an initial VL test done and results available of whom 81,932 (82%) were virally suppressed. Among those with a VL>1000 copies/mL; 6,689 (37.2%) had a follow-up VL test and 4,086 (61%) had unsuppressed VLs of whom only 1,749 (42.8%) were switched to 2nd-line ART. Lower age particularly adolescents (10-19 years) were more likely (ARR 1.34; 95%CI: 1.25-1.44) to have virologic failure.

conclusionThe study findings provide insights to implementation gaps including limitations in VL testing; low identification of high- risk PLHIV in care and lack of prompt utilization of test results. The use of electronic patient-level data has demonstrated its usefulness in assessing the performance of the national VL testing program. By end of 2017 implementation of VL testing was sub-optimal, and virological failure was relatively common, particularly among adolescents. Of concern is evidence of failure to act on VL test results that were received. A quality improvement initiative has been planned in response to these findings and its effect on patient management will be monitored.

Indexed as

Electronic Health RecordsHIV-1HIV InfectionsViral LoadAdolescentAdultAnti-Retroviral AgentsChildChild, PreschoolFemaleHumansMaleMiddle AgedRetrospective StudiesZimbabweAnti-Retroviral Agents

Identifiers

PMID33481931
PMCPMC7822242
OpenAlexW3124418414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.